Ernexa Therapeutics (ERNAW) Gains from Investment Securities (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Gains from Investment Securities of $199000.0 for Q1 2026, up 20000.0% on a YoY basis from N/an in Q1 2025, and up 1758.33% quarter-over-quarter from -$12000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Gains from Investment Securities for 17 years, with the latest figure at $199000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 20000.0% year-over-year to $199000.0; the trailing twelve-month figure through Mar 2026 stood at $199000.0 (up 54.26% YoY), and the FY2025 full-year result was $326000.0, up 1817.65% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $199000.0, up from -$12000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.9 million in Q1 2024, with the low at -$1.1 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged $92200.0 across 5 years, with a median of $55000.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 37633.33% — and 2026, when it jumped 20000.0%.
- Ernexa Therapeutics' Gains from Investment Securities stood at -$3000.0 in 2022, then plunged by 37633.33% to -$1.1 million in 2023, then jumped by 179.06% to $895000.0 in 2024, then sank by 101.34% to -$12000.0 in 2025, then soared by 1758.33% to $199000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $199000.0 (Q1 2026), -$12000.0 (Q4 2025), and $12000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199,000.00 |
| Mar 31, 2026 | 199,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 127,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | 895,000.00 |
| Dec 31, 2024 | 895,000.00 |
| Sep 30, 2024 | -831,000.00 |
| Sep 30, 2024 | -831,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | -1.13 Mn |
| Dec 31, 2023 | -1.13 Mn |